Insmed INC

Insmed announces positive 12-month safety and efficacy data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH).

Insmed Incorporated shareholders elected two directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Insmed Incorporated announced robust first-quarter 2026 financial results, driven by significant revenue growth from BRINSUPRI and ARIKAYCE, alongside positive clinical trial updates.

Insmed Incorporated announced that its Phase 2b CEDAR study of brensocatib for hidradenitis suppurativa did not meet primary or secondary efficacy endpoints, leading to the discontinuation of the HS program.

Insmed announced positive topline results from its Phase 3b ENCORE study for ARIKAYCE in newly diagnosed MAC lung infection patients, meeting primary and all multiplicity-controlled secondary endpoints.

Insmed Incorporated reported strong fourth-quarter and full-year 2025 financial results, with total revenues surging 67% year-over-year, driven by the successful U.S. launch of BRINSUPRI and robust ARIKAYCE growth, while projecting BRINSUPRI revenues to exceed $1 billion in 2026.

Insmed Incorporated announced a significant increase in total product revenues for the first quarter of 2026, primarily driven by the successful launch of Brensubri in the US, alongside continued growth in ARIKAYCE international sales.

Insmed Incorporated reports significant revenue growth in Q3 2025, driven by the US launch of BRINSUPRI and continued ARIKAYCE sales, despite increased operating losses due to substantial R&D and commercialization investments.

Insmed Incorporated reported significant revenue growth for ARIKAYCE and positive clinical trial results for brensocatib and TPIP, while continuing to incur substantial operating losses.

Insmed Incorporated's Q1 2025 results show increased ARIKAYCE sales and progress in the development of brensocatib, with a potential US launch anticipated in Q3 2025.

Insmed's Q3 2024 results show revenue growth driven by ARIKAYCE sales, alongside continued progress in clinical development programs.

Insmed's second quarter 2024 results show increased revenue and a net loss, alongside significant clinical trial advancements and strategic financial activities.

Insmed Incorporated reported significant revenue growth in 2025 driven by the launch of BRINSUPRI and international ARIKAYCE sales, alongside substantial investments in its clinical pipeline and R&D.

Insmed's 2024 10-K filing highlights the company's commitment to delivering therapies for serious diseases, advancing its pipeline, and expanding its commercial reach.

Insmed's 2023 10-K filing details the company's financial performance, clinical pipeline progress, and strategic priorities, highlighting both achievements and challenges.

William Lewis, Chair and CEO and a Director of INSMED Inc, sold 10,700 shares of common stock on July 23, 2026.

Insmed Inc. reports that CEO William Lewis sold a total of 10,699 shares of common stock on July 9, 2026, through a pre-arranged 10b5-1 trading plan.

Martina Flammer, Chief Medical Officer of INSMED Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a pre-arranged 10b5-1 trading plan.

Insmed Inc. CEO William Lewis reported the sale of company stock valued at over $1.5 million, executed through a pre-arranged 10b5-1 trading plan.

Michael Alexander Smith, Chief Legal Officer of INSMED Inc., reported a sale of 1,806 shares of common stock for $95.82 per share, executed under a pre-arranged 10b5-1 trading plan.

Insmed Inc. Director William Lewis reported a sale of 6,515 common shares for $94.03 per share, executed under a pre-arranged 10b5-1 trading plan.

Insmed Incorporated announces its 2026 Annual Meeting of Shareholders to elect directors, conduct an advisory vote on 2025 executive compensation, and ratify its independent auditor, highlighting significant 2025 commercial and clinical advancements.

Insmed Incorporated has filed a definitive proxy statement with the SEC in preparation for its upcoming annual meeting.

Insmed Incorporated is asking shareholders to approve an amendment to its incentive plan to issue 10 million additional shares, supporting continued growth and employee incentivization.

Insmed Incorporated files a definitive proxy statement with the Securities and Exchange Commission.

Insmed's proxy statement outlines proposals for the upcoming annual meeting, including the election of directors, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amendment to the incentive plan.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Insmed Incorporated's common stock as of June 30, 2026.

Darwin Global Management and Dr. Abhishek Trehan have reported a 7.8% beneficial ownership stake in Insmed Incorporated.

FMR LLC, through its subsidiaries and affiliates, has reported beneficial ownership of 13,145,166.52 shares, representing 6.1% of the outstanding common stock of Insmed Inc. as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Insmed Inc. common stock following an internal realignment.

BlackRock, Inc. has disclosed a 6.6% beneficial ownership stake in INSMED INC's common stock as of December 31, 2025.

Darwin Global Management, Ltd. and its affiliates reported an increased beneficial ownership of 9.7% in Insmed Inc., holding 20,457,445 shares of common stock.